

EXHIBIT 6

(Pt. 2)

Exhibit 6

2-5-07organogenesis.txt

1

1 UNITED STATES DISTRICT COURT
2 DISTRICT OF MASSACHUSETTS
3 * * * * *
4 BRUNO HOFFMANN, et al *
5 Plaintiffs, *
6 vs. * CIVIL ACTION
7 PHILIP LAUGHLIN, et al * No. 04-10027-JLT
8 Defendants. *
9 * * * * *

10 BEFORE THE HONORABLE JOSEPH L. TAURO
11 UNITED STATES DISTRICT JUDGE
12 MOTION HEARING

13 A P P E A R A N C E S

14 MILBERG WEISS BERSHAD & SCHULMAN, LLP
15 One Pennsylvania Plaza
16 New York, New York 10119
17 for the plaintiffs
18 By: Peter Sloane, Esq.
19 Robert A. Wallner, Esq.

20 MOULTON & GANS, PC
21 55 Cleveland Road
22 Wellesley, Massachusetts 02481
23 for the plaintiffs
24 By: Nancy Freeman Gans, Esq.

25 Courtroom No. 20
John J. Moakley Courthouse
1 Courthouse Way
Boston, Massachusetts 02210
February 5, 2007
11:05 a.m.

2

1 APPEARANCES, CONTINUED

2-5-07organogenesis.txt

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
for the defendants
By: Peter M. Saparoff, Esq.
Breton Leone-Quick, Esq.

GRIESINGER, TIGHE & MAFFEI, LLP
176 Federal Street
Boston, Massachusetts 02110-2214
for the defendants
By: Sara Jane Shanahan, Esq.

WILMER CUTLER PICKERING HALE and DORR LLP
60 State Street
Boston, Massachusetts 02109
for the defendants
By: Jonathan A. Shapiro, Esq.
Jeffrey B. Rudman, Esq.

CAROL LYNN SCOTT, CSR, RMR
Official Court Reporter
One Courthouse Way, Suite 7204
Boston, Massachusetts 02210
(617) 330-1377

0

3

1
2
3
4

I N D E X

COURT EXHIBITS

2-5-07organogenesis.txt

5

6

No. 1 Document 61

7

No. 2 Color Chart with citations 61
submitted by Mr. Shapiro

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

0

4

1

P R O C E E D I N G S

2

THE CLERK: All rise for the Honorable Court.

3

THE COURT: Good morning everybody.

4

THE CLERK: This is civil action No. 04-10027,

5

In Re: Organogenesis Securities Litigation.

6

Counsel please identify themselves for the record.

7

MS. GANS: Nancy Freeman Gans, Moulton & Gans,

2-5-07organogenesis.txt
8 for the plaintiffs.

9 MR. SLOANE: Peter Sloane of Milberg Weiss for
10 the plaintiffs.

11 THE COURT: Okay.

12 MR. WALLNER: Good morning. Robert Wallner,
13 Milberg Weiss, for the plaintiffs.

14 MS. SHANAHAN: Good morning, Your Honor. I am
15 Sara Shanahan from Griesinger, Tighe & Maffei for defendant
16 John Arcari.

17 THE COURT: Okay.

18 MR. SHAPIRO: Good morning, Judge. Jonathan
19 Shapiro and with me is Jeffrey Rudman from Wilmer Hale for
20 the following defendants: Donna Lopolito, Philip Laughlin,
21 Albert Erani, Michael Sabolinski and Alan Tuck.

22 THE COURT: Okay.

23 MR. SAPAROFF: Good morning, Your Honor.
24 Peter Saparoff from Mintz Levin for Herbert Stein,
25 defendant.

0

5

1 THE COURT: Okay.

2 MR. LEONE-QUICK: Good morning. Breton
3 Leone-Quick, also from Mintz Levin for defendant Herbert
4 Stein.

5 THE COURT: All right. It is nice to have all
6 of you here.

7 I have read I think just about everything and I
8 think I have some grasp of the underlying issues.

9 I guess a place to start is the Milberg Weiss
10 situation. It sort of permeates everything here.

2-5-07organogenesis.txt

11 The argument is made that there is a probable cause
12 situation that invites further scrutiny or scrutiny beyond
13 what you would normally have in a case like this. And then
14 on the other side we have a presumption of innocence and the
15 process, the process that is involved in these cases anyway
16 where the truth comes out.

17 And so I guess what I want to hear from the
18 defendants is where we are on that. And maybe you disagree
19 with me. It seems to me that it runs through everything.

20 MR. SHAPIRO: Yes, Your Honor. In fact, there
21 are essentially two themes that bear on the Milberg Weiss
22 situation.

23 One certainly is the indictment itself and what
24 that means and what it doesn't mean. And then there is also
25 simply the performance in this case to the extent you can

6

1 actually extract it or disaggregate it.

2 THE COURT: Well, the performance, as I read
3 it, there are a lot of things to say. I am not saying
4 nitpicky things but there are a lot of things to say which
5 we wouldn't be spending, you know, if that is all it was, we
6 wouldn't be spending twenty minutes on it if it weren't for
7 the indictment.

8 Do you -- at least that is my experience over the
9 last 35 years.

10 MR. SHAPIRO: As a general matter, yes, Your
11 Honor. And there is a certain aggregate effect here.

12 If I may propose, simply just to not to try your
13 and everyone else's patience and to motor along, what we

2-5-07organogenesis.txt

14 have done is we have come up with just a time line of some
15 of these issues so you can place them in time. That way we
16 don't have to talk about all of them unless Your Honor is
17 interested.

18 THE COURT: Go ahead. But, I mean, you are
19 the one that is interested ideally in knocking Milberg Weiss
20 out and knocking out some of these people that --

21 MR. SHAPIRO: Certainly. That is absolutely
22 correct.

23 THE COURT: So why don't you go for the
24 knockout and see if you make it.

25 MR. SHAPIRO: Okay. Well, in terms of

7

1 knocking them out, the way we would look at is they have the
2 burden of proof in the first instance to demonstrate the
3 adequacy not just of the law firm, of course, but the
4 plaintiffs and every one of the other elements that's
5 required under 23(a) and 23(b)(3) and also 23(g).

6 If I could just approach, I'll pass out this time
7 line. I have a bunch of them.

8 THE COURT: Give one to Steve.

9 MR. SHAPIRO: Sure. Hopefully they're all the
10 same.

11 (Pause in proceedings.)

12 MR. SHAPIRO: These are all events, Your
13 Honor, that are in the record. And we can give you the
14 cites for all of them but --

15 THE COURT: If you want to use this
16 (indicating) podium --

2-5-07organogenesis.txt

17 MR. SHAPIRO: That actually would be great.

18 THE COURT: Just bring it back to where you
19 are and do whatever you want to do with it.

20 MR. SHAPIRO: Now, in terms of the indictment,
21 there is one thing that we want to be very, very clear about
22 from the get-go.

23 Defendants are a defendant in a securities case.
24 This is a securities case as well. You know, we have no
25 issue whatsoever with the presumption of innocence.

8

1 It is important and it attaches to new counsel and
2 it attaches to the partners at the Milberg Weiss firm or the
3 former partners who have been indicted. So we are not
4 suggesting in any way, shape or form that the simple fact
5 that this law firm has been indicted, that a grand jury
6 found probable cause is a reason to deny the motion.

7 But on the other hand, it --

8 THE COURT: Is a reason to deny the motion?

9 MR. SHAPIRO: For certification.

10 THE COURT: For certification.

11 MR. SHAPIRO: Right. It's a bit more complex
12 than that.

13 And I think that fairly read the plaintiffs have
14 taken the position that, well, until we're tried -- and I
15 guess the trial is later this year or January next year --
16 it's irrelevant.

17 well, it's not irrelevant because the presumption
18 of innocence attaches to the law firm. But here the
19 plaintiffs are the movant and the question is is this law

2-5-07organogenesis.txt

20 firm fit to serve in a fiduciary role. Does it matter to
21 Your Honor under Rule 24, under the precedent, whether the
22 indictment and all the other things that have gone wrong in
23 this case, does that matter in determining whether they are
24 fit to serve in this case as sole lead counsel?
25 We say it matters and I will give you a couple of

0

9

1 examples.

2 One, when Milberg Weiss came forward back in '04,
3 and, again, when they filed their motion for class
4 certification in '06, this was back in May of '06, they said
5 one of the reasons they were qualified is because they're
6 the best law firm in the business in this area. And then
7 they told you that they have a lot of very noteworthy
8 clients.

9 Two of those noteworthy clients were very large
10 pension plans, pension funds. One for the state of New
11 York, one for the state of Ohio.

12 well, after the indictment the Attorney General of
13 Ohio said you're not our lawyer anymore. And the
14 comptroller of New York said you're not our lawyer anymore.

15 The way --

16 THE COURT: I think I misheard you. I thought
17 you said you are not a lawyer.

18 MR. SHAPIRO: You are not our lawyer anymore.

19 THE COURT: Okay.

20 MR. SHAPIRO: No, they certainly are a lawyer.

21 THE COURT: I mean, there has been no
22 disbarment or anything?

2-5-07organogenesis.txt

23 MR. SHAPIRO: Not that I'm aware of. The only
24 thing I've heard is that there is some inquiry in Delaware.
25 And beyond that I can't speak to that.

0

10

1 THE COURT: Okay. Go ahead.

2 MR. SHAPIRO: But the reason that these top
3 officials, the AG and the comptroller, discharged the law
4 firm was not because they had assumed that the grand jury
5 was right but because when it comes to selecting a fiduciary
6 to represent those public pension plans, and in this case to
7 represent the sole lead counsel, a class of absent
8 investors, the fact that a law firm has been indicted for
9 lying to courts does matter. It doesn't mean they did it
10 but it matters.

11 And I think that's the reason why a number of
12 courts have grappled with this very issue that Your Honor
13 posed. We have the presumption of innocence that attaches
14 to them but does that, is that the answer to the adequacy
15 question.

16 Judge Hornby, District of Maine, very late in
17 December addressed that issue head on in the In Re: Motor
18 Vehicles case. That was not unlike this case at the class
19 certification stage. There the judge on sort of an interim
20 basis saw this issue, looked at it, respected the
21 presumption of innocence, but said this firm under these
22 circumstances is not fit to continue as a fiduciary.

23 This case is actually different because there
24 Milberg Weiss wasn't alone. There was co-counsel. The same
25 in the Medtronics case. That's in Minnesota. There a

2-5-07organogenesis.txt

11

1 federal district judge came to the conclusion that under the
2 circumstances Milberg Weiss could not continue as one of a
3 handful of firms working jointly on a steering committee.

4 Here, again, they're alone.

5 The Chancery Court days before the indictment was
6 unsealed -- it was all, of course, all in the papers. The
7 Chancery Court said reading just what I'm reading in the
8 paper I wouldn't be comfortable appointing them sole lead
9 counsel. And there have been other courts as well.

10 Now, Milberg Weiss and the plaintiffs in this case
11 have provided Your Honor with a list, a fairly long list of
12 other courts that plaintiffs say stand for the proposition
13 that they are as fit and ready to go today as they were a
14 year ago.

15 If you look at each of those decisions, not one of
16 them as we read them -- and they haven't identified any --
17 appointed Milberg Weiss as sole class counsel on a contested
18 motion. In a number of them there were stipulations. It
19 wasn't litigated. I think in virtually all of them they had
20 co-counsel. And, in fact, in a number of those cases,
21 including one that plaintiffs brought to Your Honor's
22 attention, I don't know, sometime last week, Milberg Weiss
23 affirmatively said, Judge, don't worry, we have co-counsel
24 who is not indicted and that provides a safety net.

25 So there is no safety net here. They're alone.

12

2-5-07organogenesis.txt

1 Now, just taking it one step further, I think that
2 the inadequacy of counsel and the inadequacy of their
3 clients, of the lead plaintiffs, is laid bare by how they
4 reacted to the indictment.

5 They sent Your Honor a letter. They said, Judge,
6 none of the attorneys litigating the case have been accused
7 of misconduct.

8 Well, the law firm that's been litigating the case
9 is indicted. The lead Milberg Weiss partner who showed up
10 on fourteen odd pleadings in court papers on this docket in
11 this case has been indicted. He also signed the engagement
12 letters.

13 And, in fact, just a couple of weeks ago the
14 Eastern District of Michigan in the Florida ERISA case
15 looked at the same boilerplate no lawyer litigating this
16 case accused of misconduct and said that it raises questions
17 about candor and for that reason and others, declined to
18 appoint Milberg Weiss lead counsel.

19 Now, turning to the plaintiffs, I have already told
20 Your Honor that sophisticated pension plans, the ones that
21 Milberg Weiss holds out as their blue chip clients, let them
22 go. Here these plaintiffs made a decision or did not make a
23 decision to keep the lawyers. And that at least raises a
24 question as to what --

25 THE COURT: When you say "these plaintiffs,"

□

13

1 help me. Who are we talking about?

2 MR. SHAPIRO: Sure. There were four lead
3 plaintiffs.

2-5-07organogenesis.txt

4 THE COURT: You are talking about in this
5 case?

6 MR. SHAPIRO: Absolutely in this case.

7 THE COURT: You are not talking about the
8 other case?

9 MR. SHAPIRO: No, I'm talking about in this
10 case.

11 THE COURT: All right.

12 MR. SHAPIRO: The question is serious enough
13 that we would suggest that any adequate lead plaintiff,
14 anybody who wants to serve as a fiduciary demands a very
15 high standard of care and diligence and focus -- there are
16 lots of cases for that -- would have at least looked hard at
17 this issue before deciding to keep Milberg Weiss as the sole
18 lead counsel. He says they haven't done anything in that
19 regard.

20 At his deposition Mr. Madigan, one of the two
21 remaining lead plaintiffs, heard something about -- heard
22 something about an indictment but testified that he did not
23 know that the law firm was indicted. He did not know that
24 Steve Schulman who signed his engagement letter had been
25 indicted. He had never seen the indictment because lead

0

14

1 plaintiff -- lead counsel never showed it to him. So the
2 first time he saw the indictment was at his deposition.

3 Similar story for Mr. Hoffman. Doesn't know much
4 about the indictment. Trusts the lawyers. He's satisfied,
5 you know, someone else will make a judgment in the long run.
6 Maybe that's a rational decision or maybe it's not. But

2-5-07organogenesis.txt

7 here there has been no effort whatsoever to go through what
8 one would expect to be a deliberative process.

9 So you look at the indictment. You look at the
10 five cases or so that we have put in front of you in which
11 this law firm has been found ill fit to serve even with
12 co-counsel. You consider the fact that they don't have any
13 court that has found them on a litigated motion to be fit to
14 serve as sole lead counsel.

15 And then you overlay that into what has been a
16 rather extraordinary set of issues that have come up over
17 the last several months since Your Honor ordered the
18 production of documents.

19 And I think if you look at that series of issues,
20 even if this wasn't an indicted law firm with all those
21 problems, they wouldn't be adequate even looking at it sort
22 of on a standalone basis, not the plaintiffs and not the
23 lawyers.

24 There have been multiple false affidavits filed in
25 this case. I'm not suggesting it was intentionally false.

0

15

1 Maybe it was inexcusably negligent. It doesn't matter.
2 Fiduciaries are supposed to get these things right.

3 We have lost two lead plaintiffs.

4 Four plaintiffs and the law firm put in front of
5 Your Honor affidavits in 2004 when they asked you to appoint
6 them to be lead plaintiffs. Your Honor appointed them.
7 Your Honor had no reason to doubt the truthfulness of those
8 affidavits, the ones filed in '04. They were signed under
9 oath. Rule 11, PSLRA and so forth. You appointed them to

2-5-07organogenesis.txt

10 those fiduciary roles.

11 Then they filed papers last May. They said they
12 now want to also serve a fiduciary role as class
13 representative and class counsel. If you look at the papers
14 that were filed in May, May of '06, they told Your Honor
15 that this is an ideal class action. Obvious slam dunk.

16 They specifically represented that there can be no
17 doubt that the four lead plaintiffs and Milberg Weiss are up
18 to the task.

19 Then Your Honor set a discovery deadline. You said
20 all of you have to produce your stuff and you've got to do
21 it by June 30th. And no messing around and I am not going
22 to give you an extension.

23 On June 29th, the day before Your Honor's deadline,
24 another letter was sent to the court. This letter June 29th
25 said there may be some problems. And that was a real

0

16

1 understatement.

2 Almost immediately after that letter two of the
3 four supposedly ideal lead plaintiffs don't show. The first
4 to go was Dr. Conen, Richard Conen. He resigned because he
5 said he had to under the Supreme Court Dura case. Dura, of
6 course, says that Dr. Conen can't sue the defendants unless
7 he can show that the defendants caused him a loss. So that
8 took care of Dr. Conen.

9 THE COURT: He had no loss.

10 MR. SHAPIRO: I don't know whether he had a
11 loss or not. All I know is because we haven't been able
12 to --

2-5-07organogenesis.txt

13 THE COURT: He said he had no loss; isn't that
14 right?

15 MR. SLOANE: Excuse me, Your Honor?

16 THE COURT: He said he had no loss; isn't that
17 right?

18 MR. SLOANE: No, he moved to withdraw --
19 excuse me, Your Honor.

20 He moved to withdraw because he, after considering
21 the impact of Dura, we didn't feel he was an appropriate
22 class representative.

23 MR. SHAPIRO: That is the same explanation we
24 got. We can't depose him because they say he is no longer
25 up for a deposition.

17

1 THE COURT: All right.

2 MR. SHAPIRO: So for whatever reason. They
3 cite the Supreme Court case which says you have got to show
4 a connection between damages and what you're suing about.
5 And they cite that case and he is gone.

6 And we are happy to let him go because it is
7 necessary, we don't want to waste time and money and
8 everything.

9 The second to go was Richard -- excuse me -- was
10 John Bowie. John Bowie is a stock broker who filed a very
11 false affidavit about his trading in stock.

12 Back in '04 when he wanted to be lead plaintiff, he
13 told Your Honor that he had four transactions during the
14 class period, precisely four. He somehow forgot to mention
15 83 more.

2-5-07organogenesis.txt

16 So after Your Honor sets the discovery deadline,
17 they come clean and say we've got these problems. Mr. Bowie
18 puts in another affidavit in which he says I am deeply
19 sorry, I apologize and I'm embarrassed. He puts that
20 affidavit in in July and promises to correct his affidavit.

21 He never corrects his affidavit. Six days later
22 guess what? He's gone too. Personal reasons.

23 The reason all these affidavits are false -- and we
24 still haven't gotten to the most false -- the reason they're
25 all false is because we also learned on June 29th that

□

18

1 Milberg Weiss never corrected the trading documents. They
2 never corrected the trading documents before they put in
3 four plaintiffs' affidavits and one attorney affidavit and
4 like a dozen plus pleadings and court papers all based on
5 trading. They never collected the documents.

6 The case was filed in January '04. And they came
7 clean with not having the documents in June of '06. That's
8 not how fiduciaries behave, Your Honor. And that was just
9 the beginning.

10 So we went from the four ideal plaintiffs very
11 quickly within weeks down to two. The two that remain are
12 Richard Madigan and Bruno Hoffman. We have briefed this
13 extensively. It's in this fancy little chart we pulled
14 together so I won't go through it all. But they're no
15 better than the two that are left.

16 Starting briefly, Your Honor, with Richard Madigan.
17 You appointed him at the same time as you appointed
18 Mr. Bowie lead plaintiff. Mr. Madigan told you about nine

2-5-07organogenesis.txt

19 trades, all in which he said he lost money, losing trades.

20 In truth there were 55 more that didn't make it
21 onto the page. So Mr. Bowie's affidavit was 95 percent
22 wrong and Mr. Madigan's was 85 percent wrong. And things
23 got worse.

24 Mr. Madigan, like Mr. Bowie, put in another
25 affidavit apologizing, deeply embarrassed. He says he

19

1 doesn't have any memory of how it happened. It's all very
2 vague. But no worries, Your Honor, I'm going to fix it.
3 And he tells Your Honor he is working to collect the
4 documents and he will file a new affidavit.

5 Well, he didn't file a new affidavit all that fast.
6 The promise came in July, you know. It took him until after
7 Labor Day for you to get Madigan affidavit No. two.

8 Madigan affidavit No. two shows up conveniently
9 some forty hours before his deposition. So it's late. And
10 guess what? Madigan affidavit No. two is also false.

11 At his deposition Mr. Madigan realized immediately
12 that affidavit No. two was false. It included his son's
13 trades and his daughter-in-law's trades.

14 So when asked how affidavit No. two becomes false,
15 the testimony was, well, I didn't check the trading records
16 before I signed affidavit No. two.

17 All right. Well, who prepared affidavit No. two
18 for you, Mr. Madigan? I don't know. I think it was an
19 analyst but I don't know his or her name. But it was
20 someone working with Milberg Weiss.

21 So affidavit No. one is false. Affidavit No. two,
Page 17

2-5-07organogenesis.txt

22 unread, unchecked, signed, that's false. Less false but
23 still false.

24 what else did we learn at the deposition?

25 Mr. Madigan, have you ever seen this document, the

20

1 complaint, the operative complaint? I don't think I ever
2 have. Have you ever read the complaint, sir, the operative
3 complaint? My best guess is I haven't. Mr. Madigan, how
4 much money have you lost? He can't really ballpark it. He
5 thinks it might be around ten thousand but really just
6 doesn't know.

7 So he never read the complaint. He doesn't know
8 how much money he is seeking to recover from the never read
9 complaint. And he is one of the two remaining supposedly
10 ideal plaintiffs.

11 Judge Tauro, one would think that after the second
12 false affidavit that Mr. Madigan and his counsel Milberg
13 Weiss would have moved very quickly to correct it. No.

14 Ten more weeks go by. It was not until
15 Thanksgiving or the week before Thanksgiving 2006 that
16 Mr. Madigan finally put on file a trading certification that
17 the PSLRA required to have been on file before this all
18 started back in January of '04.

19 There are other reasons why he is not fit. Those
20 bear on technicalities. We've been through adequacy. It
21 all bleeds together.

22 When Mr. Madigan finally got around to disclosing
23 the 55 odd trades left out before, it turned out that they
24 were sales. They were class period sales. Those class

2-5-07organogenesis.txt

25 period sales, when we had to hire an expert to help us

21

1 figure it all out because they didn't do the job, it turned
2 out that he was net up. He made money. He lost some money
3 on some sales, made more money on other sales, was net up, I
4 don't know, \$15,000.

5 Your Honor, in a case in which the plaintiff is
6 suing defendants for harm because they supposedly
7 manipulated the stock, if the plaintiff makes more from the
8 supposedly inflated stock than he lost, he is not a
9 plaintiff. He doesn't have standing. Standing comes first.
10 That's Judge Saris' AWP case, the Enron case, Allen, Lewis,
11 some Supreme Court cases.

12 He's better off. And none of this was disclosed
13 until -- well, the problem was disclosed in June '06. The
14 truthful affidavit or what seems to be the truthful
15 affidavit took until Thanksgiving '06. We never filed a
16 motion to dismiss based on a lack of standing because we
17 never knew because we were trusting the affidavits
18 presumably just like the Court was.

19 Plaintiffs' response to this is, well, it all goes
20 to damages. We will deal with that later. It's just a
21 measure of damages. It doesn't blow up the case.

22 Your Honor, we think that's legally wrong. The
23 vast majority of cases, certainly since Dura but in the last
24 four or five years, have all held that the, you know,
25 LIFO -- that's the analysis our experts use -- that the LIFO

2-5-07organogenesis.txt

22

1 methodology is right.

2 We're not aware of any case after the Supreme Court
3 Dura decision that's held that their FIFO is right. And in
4 some sense, Your Honor, it doesn't matter for class
5 certification because there is a bona fide substantive
6 dispute. They've got some cases in the '30s in the tax
7 court. We have got, you know, four or five cases and Dura,
8 you know, more recently.

9 Even if one were to credit their cases as being
10 smarter or still binding, you still have a very substantive
11 dispute and now we have a battle of the experts. We have
12 got dueling affidavits on file.

13 So whether you look at it as standing, you know, a
14 plaintiff with standing can't represent himself much less a
15 class he is on, or whether you view it as a unique defense,
16 a real defense, he is certainly not typical and can't serve
17 as a class representative.

18 And finally with Mr. Madigan, he is not typical
19 because he didn't buy on the open market information in a
20 typical way. Mr. Madigan testified at his deposition that
21 he met two or three times with the top management of
22 Organogenesis initially. He met them at the company's
23 headquarters.

24 And he testified that having a chance to meet the
25 top management gave him some comfort about his investment

23

1 decision. That makes him atypical of the open market

2-5-07organogenesis.txt

2 investor who reads Yahoo or Wall Street Journal but doesn't
3 get comfort by spending time in the executive suite. He is
4 not adequate. And he's not typical.

5 Turning to Mr. Hoffman. Mr. Hoffman is the only
6 plaintiff that's before Your Honor who near as we know did
7 not file a false affidavit. But the absence of false
8 affidavits doesn't make him adequate and doesn't make him
9 typical.

10 He is certainly not a typical investor who makes an
11 investment decision in reliance on open market information.
12 In fact, Mr. Hoffman never decided to invest in
13 Organogenesis at all. He wound up a shareholder because he
14 gave his money and full discretionary trading authority to a
15 broker or investment advisor.

16 The investment advisor without even talking to
17 Mr. Hoffman knew some folks at Organogenesis and spent
18 Mr. Hoffman's money on Organogenesis stock.

19 Mr. Hoffman testified that he had never even heard
20 of Organogenesis until he saw that strange name on a
21 brokerage statement. And at some point thereafter he fired
22 the broker.

23 He is also not typical because the class period is
24 28 months and he stopped buying stock after six of them.
25 This is a purchaser class. The allegation, the complaint

0

24

1 that Your Honor sustained was sustained on the basis that
2 investors purchased based on misleading statements. And
3 plaintiff alleged 39 of the statements. He stopped buying
4 after nine of the statements. So he doesn't have standing

2-5-07organogenesis.txt

5 to sue anybody for the truth or falsity of the back thirty,
6 the statements made during the twenty odd months that he
7 wasn't buying.

8 Co-counsel Ms. Shanahan for defendant Arcari now
9 has a motion for summary judgment because one of the
10 defendants, her client Arcari, didn't join the company until
11 he stopped buying. So he doesn't even have standing to sue
12 one of the defendants.

13 And he's also not adequate, Your Honor, because he
14 didn't do his job, under Carematrix, under Critical Path,
15 under the long string of cases that say that a class
16 representative needs to exercise diligence and care as a
17 fiduciary of the highest order.

18 He may have been honest on his affidavit but he has
19 no idea why all his co-plaintiffs are dropping off and why
20 there are all these false filings in the case.

21 An adequate plaintiff at some point says what's
22 going wrong with this case on my watch.

23 At his deposition Mr. Hoffman wanted nothing of
24 that. It's not me. I don't know. It the lawyers' job.
25 Abdication, your problem. That's not consistent with Rule

25

1 23 or the case law.

2 Mr. Hoffman also testified that he never spoke to
3 his co-lead plaintiffs for more than two years after this
4 case was filed. The Carematrix decision says co-lead
5 plaintiffs need to run the show. Sonus says the same thing.
6 They need to run the show. They need to exercise control,
7 be on top of things, not let the lawyers, you know, run

2-5-07organogenesis.txt

8 wild.

9 They never spoke until sometime in '06 before his
10 deposition. And that was a ten-minute call.

11 Parenthetically Mr. Madigan didn't remember
12 speaking to him ever. But a ten-minute call after all
13 that's happened in this case two and a half years down the
14 pike is not adequate.

15 And finally, Your Honor, looking at the false
16 affidavits in the context not only of this case but of other
17 cases, there is still a false attorney affidavit that's on
18 file with this case. It's been on file since like March of
19 '04. It says plaintiffs have losses of some number more
20 than two hundred thousand.

21 It includes losses of, you know, two plaintiffs who
22 have fled and it includes apparently losses of Mr. Madigan
23 who certainly didn't lose as much as they said he did and we
24 think he didn't lose anything. That's still on file.

25 And then you look at the Sonus decision. In Sonus

0

26

1 Judge Wolf said this should never happen again. And what
2 happened in Sonus pales in comparison. That was one wrong
3 affidavit. It omitted post class period sales.

4 Here between Mr. Bowie and Mr. Madigan they
5 disclosed thirteen and left out 138. And Mr. Madigan filed
6 another false one. And lead plaintiffs still -- excuse
7 me -- counsel still has a false affidavit on file from '04.

8 The response to that was, "People are human." And
9 also that is inevitable. It's happened before and it will
10 happen again.

2-5-07organogenesis.txt

11 That is not care and that's not diligence. There
 12 is no way these affidavits could possibly have been right
 13 because a lawsuit based on investment losses was filed and
 14 affidavits claiming investment losses were signed under oath
 15 and filed without anyone checking the trading records so
 16 that's inadequate as well.

17 The law, we would say, Your Honor, the law is on
 18 our side for the defendants because it puts the burden on
 19 the plaintiffs' side of the V. They have to show every
 20 element under Rule 23. That's the Tardiff decision, First
 21 Circuit '04. Polymedica, you know, emphasizes the
 22 importance in '05 of, you know, needing to check every box.

23 Just last year the Second Circuit -- I'm not
 24 suggesting it's binding on you -- but the Second Circuit
 25 says it's not even enough to show every element but you

27

1 can't do, quote, some showing. It's got to be robust.

2 They bear the burden on every element. It needs to
 3 be rigorous because you're looking at a set of defendants
 4 who need to defend themselves, that's our job, but we're
 5 spending hundreds of thousands of dollars chasing records
 6 they never collected.

7 And it may be in a case where two plaintiffs are
 8 gone, a third may not have standing at all and one may only
 9 have standing for six out of 28 months. They need to
 10 affirmatively show every single element under Rule 23.

11 And they haven't shown typicality for either
 12 plaintiff. They haven't shown adequacy for either of the
 13 two remaining plaintiffs. And their sole lead counsel just

2-5-07organogenesis.txt
14 isn't adequate.

15 Thank you, Your Honor.

16 THE COURT: Now, what will you have me do?
17 You are very eloquent. You have made a very good argument.

18 Now, what is the bottom line? What would you have
19 me do? Dismiss the case? What do you have in mind?

20 MR. SHAPIRO: I believe sort of under the law
21 in the cases that we've looked at the appropriate course is
22 you have to deny the motion. They still have individual
23 cases on file. They brought cases in their own name and on
24 behalf of a putative class. But Your Honor I believe has to
25 deny the motion for certification because they haven't shown

28

1 each element.

2 THE COURT: Then what happens to the case?

3 MR. SHAPIRO: Then we still have pending
4 individual complaints.

5 Mr. Bowie who fled still has a lawsuit against my
6 client. I mean, it's a different lawsuit. But then it
7 would be -- presumably the parties would confer and see how
8 are we going to go about dealing with these individual
9 lawsuits.

10 THE COURT: Okay.

11 MR. SHAPIRO: One final note, Your Honor.

12 THE COURT: Yes.

13 MR. SHAPIRO: They don't have another new
14 plaintiff. They said back in July that there are, quote,
15 hundreds or perhaps thousands of plaintiffs who could be
16 adequate here but they have never come forward with any of

2-5-07organogenesis.txt
17 them. That's docket No. 143 on page 14.

18 They filed a motion. They haven't proved it up.
19 Half of it is gone already. It needs to be denied.

20 THE COURT: Did you want to be heard now or do
21 you want to wait? Or do you want to be heard at all?

22 MS. SHANAHAN: I can be very brief, Your
23 Honor, or we can move on to plaintiffs.

24 THE COURT: Well, I want to give plaintiffs a
25 chance to respond to everything, so go ahead.

29

1 MS. SHANAHAN: Okay. Well, just -- I'll defer
2 to the plaintiffs now and go at the end, if that's better
3 for the Court.

4 THE COURT: All right.

5 MR. SHAPIRO: Thank you, Judge Tauro.

6 THE COURT: Thank you.

7 MR. WALLNER: Thank you, Your Honor. May I
8 address the Court here or would you rather me go --

9 THE COURT: Any place that you feel
10 comfortable.

11 MR. WALLNER: Thank you, Your Honor.

12 May it please the Court, my name is Robert Wallner
13 and I'm representing the plaintiffs in connection with the
14 Rule 23 motion for class certification.

15 Counsel for the defendants has made a number of
16 points and a number of important points that I'd like to
17 address.

18 The Milberg Weiss firm has been indicted, Your
19 Honor. And we take these charges very seriously.

2-5-07organogenesis.txt

20 Mr. Schulman who was on the original papers has
21 resigned from the firm. Prior to that he took a leave of
22 absence. Mr. Bershad likewise has taken a leave of absence.
23 The counsel who have been litigating this case on a
24 day-by-day basis in the current time frame after
25 Mr. Schulman took his leave of absence are not implicated in

0

30

1 the indictment. Indeed, the U.S. Attorney presumably
2 recognizing a presumption of innocence that applies to these
3 cases stated in the transcript that is before Your Honor
4 that you would hope that other persons at the firm would
5 step forward to litigate. And that's exactly what has
6 happened.

7 The trial in the Milberg Weiss case is presently
8 scheduled for January of 2008. There is some motion
9 practice that is scheduled or may be scheduled to take place
10 before that aimed at the allegations but the trial itself is
11 now set for January 2008.

12 And that is important, Your Honor, because under
13 the schedule that Your Honor has established, discovery in
14 this case, in the Organogenesis case, is set to conclude in
15 April of 2007. And assuming that that schedule is met, even
16 assuming some modest amendment to that schedule, it is
17 highly likely that summary judgment proceedings or even a
18 trial in this action will conclude prior to the scheduled
19 trial in the Milberg Weiss case now set for January 2008.

20 Indeed, at one of the pretrial hearings Your Honor
21 had set April of 2007 as the date for filing of summary
22 judgment motions. And, therefore, the prospect that Milberg

2-5-07organogenesis.txt

23 weiss will be unable to prosecute this case because of the
24 case against it is highly remote.

25 I believe, Your Honor, that the record shows -- and

31

1 I want to deal with what he calls "false certifications" in
2 a moment. But I would submit, Your Honor, that the record
3 shows that the firm has prosecuted this case effectively and
4 successfully from the time of the case through today, the
5 day that brings us here today.

6 We survived a very aggressive and rigorous motion
7 to dismiss, that Your Honor had dismissed some defendants
8 but for the principal part the complaint is intact.

9 We have been engaged in document discovery. Our
10 proposed class representatives Mr. Madigan and Mr. Hoffman
11 have been deposed.

12 And incidentally, Your Honor, Mr. Hoffman and
13 Mr. Madigan are in the court today. And they're sitting
14 behind the bar. And certainly if the Court has any
15 questions, they're available.

16 So I think the record in this case is quite good in
17 terms of how the firm, consistent with its reputation in the
18 past, has prosecuted this case.

19 Counsel points out that Mr. Madigan filed what
20 counsel called false certifications. We take that very
21 seriously. Mr. Madigan did file a certification at the
22 beginning of the case that for the most part had problems
23 because he did not include the sale transactions. And,
24 indeed, as we pointed out in our papers, the word "sale" was
25 crossed out so there was a misunderstanding.

2-5-07organogenesis.txt

32

1 In the second certification he corrected for the
2 most part those problems but based upon the work of an
3 expert Mr. Marek, who himself has put in a report, there
4 were a couple -- there were some transactions of Mr. Richard
5 Madigan's son who is also named Richard but I think it's
6 Richard, Jr. who has the same street name and that was in
7 error. And these errors do happen. There is no suggestion
8 that the current extant list of transactions is accurate.

9 As for Mr. Hoffman, there is no suggestion that
10 anything about his certification is wrong, improper or
11 otherwise misleading in any way.

12 With respect to Mr. Madigan, Your Honor, there is a
13 dispute as to whether his transactions show damages or loss
14 under applicable law. And the dispute here, Your Honor, is
15 very similar to the dispute that Your Honor heard in another
16 case before this court where my firm was involved. It's
17 called the CVS case. And it's a dispute between FIFO,
18 F-I-F-O, and LIFO, L-I-F-O. And these are different ways of
19 an accounting for transactions. First in first out or last
20 in first out.

21 And it goes to the issue of whether the sale that
22 you match is matched to the most recent purchase or some
23 other purchase. We have briefed the issue and have showed
24 the Court I submit that LIFO is plainly an adequate and
25 appropriate manner of calculating damages. And Your Honor

33

2-5-07organogenesis.txt

1 accepted that in the CVS case. And the IRS uses that and
2 numerous courts have also used that.

3 Perhaps the jury at some juncture down the road or
4 perhaps in some motion in limine or summary judgment
5 proceeding the Court will have an opportunity to address
6 that issue, or the jury will. But at this stage there is no
7 question that Mr. Madigan has standing. Indeed, Mr. Marek
8 showed that his losses are about a hundred thousand dollars.

9 So we have a good faith basis to show that
10 Mr. Madigan has been damaged and that he has losses that are
11 substantial and clearly has standing.

12 They also, defendants also make the argument that
13 Mr. Hoffman had a financial advisor and that it was a
14 discretionary account with Mr. Hoffman's financial advisor
15 making decisions to purchase the stock in Organogenesis.
16 But that is a rather typical type of arrangement.

17 These class representatives are businessmen.
18 They're not lawyers. They're not professionals in the stock
19 market. And it's rather typical and no doubt many members
20 of the class have financial advisors upon whom they rely.

21 What the defendants would have to show, Your Honor,
22 and which they haven't shown, is that there is something
23 about the purchases in this case such as the receipt of
24 inside information of a material nature that renders
25 nugatory the statements that we say and the omissions that

0

34

1 we say inflated the market price of Organogenesis stock
2 during the class.

3 For example, in their papers the defendants say
Page 30

2-5-07organogenesis.txt

4 that one of the plaintiffs, either directly or through his
5 financial advisor, was told about a crossover, that the
6 company at some point would become profitable. Yet that is
7 very similar to what we are complaining about in this
8 lawsuit.

9 The defendants stated that at some point in time in
10 the future the company would become profitable. We
11 challenged that statement.

12 What they didn't disclose, Your Honor, is that each
13 time they sold the product at issue -- and it's a skin
14 therapy product -- the company was losing money.

15 What the defendants did not disclose, Judge Tauro,
16 is that the financial condition of the company was quite
17 weak. They told us that they have some financial
18 arrangements with Novartis, a marketing partner, but did not
19 disclose the difficulties that the company would have in
20 exercising those financial options called the put option.

21 So they didn't disclose the truth about what was
22 happening. And, therefore, whether Mr. Hoffman had a
23 financial advisor who was duped or whether Mr. Hoffman
24 individually would have made the purchase decision, the fact
25 of the matter is that what was being told to Mr. Hoffman's

0

35

1 advisor is quite similar to what the market was being told.

2 They also challenged Mr. Hoffman because they say
3 that he purchased towards the beginning part of the class
4 period rather than at the end. And any time, Your Honor,
5 there is a class period that spans several years, as it does
6 here, invariably we are going to have situations where

2-5-07organogenesis.txt

7 people who bought towards the beginning did not buy at a
8 time when each of the offending statements was made.

9 But what the law teaches us, and one of the leading
10 cases is Blackie v. Barrett, is that when there is a course
11 of conduct where the defendants like they're alleged to have
12 done here make misrepresentations and omissions about the
13 financial condition of the company and about the marketing
14 and manufacturing problems, we don't have to have a
15 plaintiff who purchased on each day during the class period.

16 If that were the law, we would wipe out class
17 certification. That would be the end of Rule 23.

18 I wanted to briefly address their statements about,
19 the defendants say it was about the defendants -- the
20 defendants say it was that the plaintiffs don't know enough
21 about this case or cares enough about the indictment.

22 They're not lawyers. They have put in declarations
23 stating that they have confidence in Milberg Weiss. There
24 is a presumption of innocence that we urge this Court to
25 apply because, Your Honor, what I'm concerned about is

0

36

1 notwithstanding the U.S. Attorney's statement that
2 individuals at the firm should step up to the plate and
3 litigate these cases, I am concerned that the rule that the
4 defendants urge upon this Court is in effect a rule that
5 says if the firm has been challenged by the U.S. Attorney,
6 even if there is probable cause, if it's not proven, it
7 doesn't matter, Milberg Weiss, you must close down.

8 And I don't believe that that is the law that
9 applies here. Counsel --

2-5-07organogenesis.txt

10 THE COURT: In this type of case.

11 MR. WALLNER: Pardon me?

12 THE COURT: In this type of case. I think
13 that, that is what I gather. Not that anybody is ready to
14 turn their back on the presumption of innocence, the fact
15 that you have to prove a case beyond a reasonable doubt.

16 I think what he was suggesting to me -- and he can
17 speak for himself in a moment -- is that in this type of
18 case where a few people are given so much trust and
19 authority to litigate the financial problems of hundreds of
20 others, that there is a heightened standard that we should
21 look at when a situation, an unfortunate situation like has
22 this happened, a law firm being indicted.

23 MR. WALLNER: Your Honor, even accepting --

24 THE COURT: Not to demean the personal injury
25 part; but, I mean, it isn't an intersection case where one

37

1 of your skilled lawyers, and some of them were very, very
2 skilled, and tried those cases, of course, is going to try a
3 case. Here you have much more at stake. And I don't mean
4 to sound pedantic.

5 MR. WALLNER: I appreciate that.

6 THE COURT: I am telling you what you know
7 anyway.

8 MR. WALLNER: Sure.

9 The fact of the matter is, Your Honor, that while I
10 can appreciate the distinction between the so-called
11 personal injury case and the case here, I think this Court
12 should be guided by what many other courts have done. Not

2-5-07organogenesis.txt

13 every court to be sure, which is to say there is a
14 presumption of innocence.

15 Milberg Weiss has been able to litigate the case.
16 We overcame the motion to dismiss. And the trial in the
17 Milberg Weiss case is set for next year at a time when this
18 case, assuming Your Honor's schedule sticks, even with some
19 modifications, may well be over.

20 I think, Your Honor, that the issue of class
21 certification in terms of who the representatives are, who
22 the counsel is, how they're performing, can be assessed
23 throughout the course of the litigation.

24 THE COURT: Who is going to be the class
25 representative? Who is going to be the class plaintiffs?

38

1 MR. WALLNER: Mr. Madigan and Mr. Hoffman.

2 THE COURT: Just two?

3 MR. WALLNER: Yes. The representatives. And
4 that's not unusual. In many cases there is one proposed
5 class representative and in others there are multiple.

6 So we have what I believe to be highly adequate
7 class representatives. They don't challenge anything about
8 Mr. Hoffman's certification. And we have a case which
9 likely can be concluded at least through trial prior to the
10 time of the Milberg Weiss case.

11 If moving down the road the Court is concerned --

12 THE COURT: Now, the defendants are asking to
13 have -- who are you asking to have deposed? Forgive me
14 for --

15 MR. SHAPIRO: Your Honor, we have pending
Page 34

2-5-07organogenesis.txt

16 motions to depose Mr. Conen, Dr. Conen who is one of the
17 plaintiffs, and Mr. Bowie.

18 And I would say the bigger point here, the problem
19 with the wait and see approach is what happens, even if
20 standing were a jury question, what happens if he doesn't
21 have standing? What happens to the rest of case post
22 judgment? What if after a January trial Milberg Weiss
23 pleads guilty or gets convicted?

24 I mean, we have a pretrial before Your Honor in
25 April. We've been making time and we're ten weeks out and

□

39

1 they still don't have a good plaintiff and they have a law
2 firm that's representing them that no court has appointed to
3 a fiduciary duty -- a fiduciary role as sole counsel.

4 THE COURT: Okay. I am going to give you an
5 opportunity to speak in a minute. I just wanted an answer
6 to my question.

7 Go ahead.

8 MR. WALLNER: Yes. They are seeking to take
9 depositions of people who are not proposed class
10 representatives.

11 Mr. Hoffman's certification they don't challenge.
12 He is highly adequate. We believe Mr. Madigan is highly
13 adequate too.

14 What Mr. Shapiro's statement to Your Honor focuses
15 on is the prospect that at the Milberg Weiss trial in
16 January 2008, well after this case may be over, something
17 will happen that will affect this case. But this case will
18 be over.

2-5-07organogenesis.txt

19 If, for example, Your Honor, we go to trial in the
20 summer and we win and we win all the damages and then next
21 year in 2008 there is a trial against Milberg Weiss which
22 turns out hypothetically adversely to Milberg Weiss, that
23 judgment is still sacrosanct. We will have recovered on
24 behalf of the class.

25 Let's flip it. Let's suppose we go to trial, Your

40

1 Honor, and we lose the trial. Or let's suppose there is a
2 summary judgment motion made by the defendants and they get
3 summary judgment in their favor. Then the case is over.

4 So the prospect that something horrific could
5 happen to Milberg Weiss next year I submit should not inform
6 the Court about the propriety of moving forward at this
7 time, particularly where I submit my firm has prosecuted
8 this case effectively to the ultimate benefit of the class
9 members. We have sustained --

10 THE COURT: What about the assertions that
11 your law firm hasn't complied with the discovery orders? I
12 don't have it at my fingertips, but substantial discovery is
13 alleged not to have been timely produced, produced in a
14 timely fashion.

15 MR. WALLNER: Your Honor, I would ask Mister
16 --

17 THE COURT: Going right up through today as I
18 take it.

19 MR. WALLNER: Mr. Sloane in the context of the
20 discovery motions is certainly prepared to discuss that.

21 But I don't think that the challenge --

2-5-07organogenesis.txt

22 THE COURT: That is all part of the
23 qualifications of the firm to go forward. I mean, if you
24 have got a close case, if you have got a close case, you
25 know, given the indictment and the presumptions and all

□

41

1 that, and my sensitivity to it. I mean, I have had your
2 firm before me many times over the years. Always very
3 satisfactory. Never anything but a good experience.

4 But a different ball game today. And if on top of
5 that load that you have to carry, because it is your burden
6 to reach the top, we have, for whatever reason, the failure
7 to do the routine discovery things that have to go on in
8 every case. Maybe it is overload because of the
9 circumstances. I could understand if it were.

10 But if it exists, maybe they should not be in the
11 case.

12 MR. SLOANE: Your Honor, may I respond to that
13 particular point?

14 THE COURT: You will have -- I want to give
15 him an opportunity to finish.

16 MR. WALLNER: Yes.

17 THE COURT: You can have all the time you
18 want.

19 MR. WALLNER: Yes. Mr. Sloane is familiar
20 with the discovery issue. And may I defer to my partner
21 Mr. Sloane?

22 THE COURT: Do you want to stop -- you don't
23 have to answer my question now. If you want to go on with
24 the rest of your argument --

2-5-07organogenesis.txt

25 MR. WALLNER: Yes, sure.

0

42

1 THE COURT: If you want to pause, you may
2 pause.

3 MR. WALLNER: May I pause? Mr. Sloane will
4 address that. Thank you.

5 MR. SLOANE: I just wanted to point out, Your
6 Honor, that the plaintiffs have complied with all of their
7 discovery obligations in this case. And I am not aware of
8 any motion that the defendants have made that we haven't
9 complied with that or that there is any discovery
10 outstanding --

11 THE COURT: There is no motion to compel.

12 MR. SLOANE: We haven't -- or that there is
13 any suggestion that there is discovery that they are
14 entitled to that we have not provided.

15 THE COURT: Well, let's get an answer to that.

16 MR. SHAPIRO: Actually, Your Honor, there is
17 very much a suggestion.

18 On June 30th they were supposed to give us trading
19 records. Rule 11 required them to have those trading
20 records in January '04. They sent a letter saying they were
21 just collecting them.

22 We sent about \$100,000 or more going to collect
23 their trading records from third parties and then having to
24 hire someone to figure all this out.

25 And that is not effective and successful

2-5-07organogenesis.txt

43

1 prosecution of this case.

2 MR. SLOANE: Excuse me, Your Honor.

3 The plaintiffs, all of the plaintiffs produced the
4 documents that were in their possession, including documents
5 relating to their trading in the stock by January -- June
6 30th, excuse me.

7 There were records that were records regarding
8 their trading that were not in their possession and that we
9 sought from their brokers. And defendants also subpoenaed
10 their brokers. We also subpoenaed some of their brokers.
11 And those documents were provided after June 30th but that
12 was because they were provided by the brokers, not because
13 we did not live up to our obligations under the discovery
14 order.

15 And I would like to point out that defendants, the
16 defendants did not produce eight boxes of documents that
17 they should have produced under the discovery order till
18 months after June 30th. So the suggestion that we have not
19 been complying with our discovery obligation is not a fair
20 one, Your Honor.

21 MR. SHAPIRO: Judge, it absolutely --

22 THE COURT: I am going to give you a chance to
23 respond.

24 MR. SHAPIRO: Fair enough.

25 THE COURT: Go ahead.

44

1 MR. WALLNER: I just wanted to conclude --

2-5-07organogenesis.txt

2 thank you, Your Honor. Robert Wallner. I just wanted to
3 conclude with the attack on the due diligence and care of
4 the plaintiffs. They are laymen. They are not lawyers.

5 In cases like this it is --

6 THE COURT: But the law has changed. They are
7 supposed to have more than a passive interest. I mean,
8 there is a burden to get yourself involved. I thought that
9 was the spirit of this action.

10 MR. WALLNER: They have been involved, Your
11 Honor, understanding that they are laymen. They are not
12 lawyers. And they have produced discovery --

13 THE COURT: Well, presumably they are very
14 successful businessmen who know how to read and know better
15 than to get snookered by anybody. And so if there is going
16 to be a presumption, I will give them that presumption.

17 Those are the two gentlemen seated in the back?

18 MR. WALLNER: Behind the bar (indicating),
19 yes.

20 THE COURT: They even look smart just sitting
21 there.

22 (Laughter.)

23 UNIDENTIFIED SPEAKER: I am smart.

24 (Laughter.)

25 MR. WALLNER: And they have taken this case

0

45

1 very seriously. They confer with plaintiffs' counsel. They
2 sat for depositions. They answered lots of questions.

3 Mr. Hoffman came up today from the New York area.

4 Mr. Madigan is more local. And they are prepared to

2-5-07organogenesis.txt

5 continue to prosecute effectively in this case.

6 The issue I submit, Your Honor, at the end of the
7 day is where you have a case where there has been massive
8 fraud alleged against the company and its individuals where
9 the action has been sustained on a motion to dismiss and
10 where the shareholders have sustained substantial financial
11 losses. This company as we know went into bankruptcy.
12 whether there is any remedy left for the class --

13 THE COURT: But you keep tapping on the motion
14 to dismiss. That is not a victory, denial of a motion to
15 dismiss. I have to look at what is alleged and take it to
16 be true.

17 MR. WALLNER: That's correct.

18 THE COURT: As long as somebody can articulate
19 some language that passes minimum muster, then you survive
20 the motion to dismiss.

21 A motion for summary judgment is a different ball
22 game.

23 MR. WALLNER: That's correct. That's correct.

24 But I submit, Your Honor, that they have a
25 sufficient understanding of the case. They conferred with

46

1 counsel. And Mr. Madigan did make some mistakes. There is
2 no suggestion that Mr. Hoffman made any mistakes.

3 And in the absence of a Rule 23 certification, from
4 a practical perspective the ability of class members to
5 vindicate their rights in this case will be eliminated.

6 And we request that Your Honor grant the Rule 23
7 motion. Thank you.

2-5-07organogenesis.txt

8 THE COURT: Okay. Do you want to be heard

9 again? Go ahead.

10 MR. SHAPIRO: Judge Tauro, the answer to every
11 mistake that's made on the plaintiffs' side can't be that an
12 investor has lost money.

13 The rule requires them to show each and every
14 prong, not to say it is not proper, not plead, but something
15 substantial. More than a mere showing.

16 At every turn this has been the response to a
17 misstatement. An investor has lost money. The defendants
18 are liars and we'll fix it all later on. That's not how it
19 works.

20 They started this case accusing others of fraud
21 with false affidavits, still one on file. They can't now
22 just say, well, they're laymen.

23 Well, Mr. Bowie wasn't a layman. He was a stock
24 broker who got it 95 percent wrong. Oh, by the way, he was
25 Mr. Madigan's stock broker.

□

47

1 It's not enough to say that they're here in the
2 court today and showed up for a deposition. They never
3 spoke according to Mr. Madigan before his deposition. And
4 they only spoke for ten minutes once on a call according to
5 Mr. Hoffman. This may be the first time they ever laid eyes
6 on each other.

7 They are not controlling the lawyers. Your point,
8 Your Honor.

9 The whole idea was that the statute is going to
10 come up with some sort of protections to put the litigants

2-5-07organogenesis.txt

11 in charge of the lawsuit like it is in other cases.

12 Here no one is minding what the lawyers are doing.

13 Mr. Hoffman who is inadequate because he says it's all

14 counsel's job, not my problem.

15 Mr. Madigan said he didn't read the complaint.

16 That's not minimal knowledge of what's going on in the case.

17 Now, with respect to the presumption of the
18 innocence, and we will see where all this goes, it's exactly
19 right. It is a higher standard. The question isn't whether
20 this law firm will some day be convicted. We only have the
21 facts that are in front of us now.

22 We have the benefit of hindsight. We never have
23 foresight. There is a trial that's scheduled, a criminal
24 trial I gather, for ten, twelve, eleven months from today.
25 It's very serious. The allegations of that, people in

48

1 courts were lied to. One hundred fifty class action
2 lawsuits. Legal fees in excess of, I don't know, a hundred
3 million dollars.

4 Two clients have pled guilty accounting for more
5 than, you know, seventy of these cases. I don't know why
6 they pled guilty. But this is serious.

7 There is not a single case that has been brought to
8 the fore where this law firm has been affirmatively
9 appointed by any court as sole counsel in any case under
10 Rule 23. And the standard is higher. It's not whether you
11 have been convicted.

12 Surely whatever Rule 23(g) means and whatever
13 Rule 23(a)(4) means, it doesn't mean that anybody is

2-5-07organogenesis.txt

14 qualified if they haven't yet, you know, been convicted,
15 sentenced and, you know, and filed and had denied their
16 posttrial motions.

17 With respect to the standing, it's sort of the same
18 issue. Oh, Mr. Madigan, we'll figure out FIFO or LIFO later
19 on.

20 Well, first, with great respect, they are just
21 wrong that LIFO is not like an appropriate methodology.
22 There have been five cases within the last two or three
23 years, most of which post Dura which say LIFO is what you do
24 and FIFO is, you know, what the IRS does under different
25 circumstances.

0

49

1 Nothing like as I read your CVS opinion. Your
2 Honor knows what you meant in CVS. I am not going to --

3 THE COURT: I didn't really decide the issue.

4 MR. SHAPIRO: I don't think you -- well,
5 whatever you said in CVS, I could not read that to say that
6 you now say it's open season for lead plaintiffs who don't
7 read complaints, repeatedly file false affidavits and don't
8 know each other. And it didn't seem to displace anything
9 about standing. And it came before Dura.

10 When I read the transcript that Your Honor did in
11 CVS, you seemed to focus on the common liability and the
12 allegation of the inflated stock.

13 The Dura decision they don't deal with in their
14 papers.

15 The Dura decision 2005 says that common themes and
16 liability and inflated stock alone isn't enough. To be a

2-5-07organogenesis.txt
17 plaintiff, you have to plead and later on you have got to
18 prove that you bought the stock at the inflated price
19 because of the statement and then you lost money. You've
20 got to tie it all up. It's kind of like Prosser, you know,
21 proximate cause.

22 So to say it's all going to be worked out later
23 isn't acceptable. And with respect to the different
24 scenarios that Milberg Weiss will win millions of dollars
25 and it will all be great or Milberg Weiss will lose and it

□

50

1 will all be great, well, what if we win and we get a
2 judgment in our favor and then it's collaterally attacked.
3 That's not trivial. That's what Judge Hornby was focused on
4 in part when he didn't want to, even as one handful of
5 counsel in the Maine case motor vehicles. Medtronics said
6 that. I believe that the Key v. Gillette case from years
7 back from the First Circuit said that. There are other
8 cases as well.

9 We have an interest in finality also. You can't
10 even settle a case under these circumstances, Andrews and so
11 forth, I mean, you can't buy the peace.

12 And I think that's why Milberg Weiss, including in
13 the cases it cites to you, it's telling courts, told Judge
14 O'Toole in one of our cases, no worries, we've got
15 co-counsel. They're all alone here.

16 Finally, Your Honor, we rest on our papers with
17 respect to this inside trading issue. We very clearly put
18 in an evidentiary record to show that this broker that
19 Mr. Hoffman relied on is precisely the problem. He breaks

2-5-07organogenesis.txt
20 the chain. He's at least subject to atypical, you know,
21 defense as an atypical plaintiff.

22 That broker by the way has the distinction of being
23 subject to cease and desist fraud orders from both the SEC
24 and the Federal Reserve for not being truthful to clients.
25 That same broker was making written promises that contrast

51

1 starkly with the public statements. We've briefed that
2 including why this case is not like Swack.

3 And I guess I would just close by saying they have
4 to prove every one of these elements. They haven't done it.
5 Saying that somebody who is absent and not here is going to
6 lose out is not the answer. That's the reason why they
7 should have gotten it right back in 2004 when the PSLRA and
8 your very early Greebel decision under it said they needed
9 to get it right and file something honest at the outset.

10 THE COURT: Okay. Anybody else scheduled to
11 speak or not scheduled?

12 MR. WALLNER: Your Honor, I just wanted to
13 spend thirty seconds responding to Mr. Shapiro's point --

14 THE COURT: Go ahead.

15 MR. WALLNER: -- about the Swack case. The
16 Swack case which is a decision in the District of
17 Massachusetts that we cite in our papers, the Transkaryotic
18 decision also of this court, support the proposition that
19 even if a financial advisor or a purchaser has access to
20 information outside the public documents, unless that
21 information is so different and is going to become the focus
22 of a trial, it doesn't matter.

2-5-07organogenesis.txt

23 In the real world it's not surprising that
24 investors would have sources of information. They speak to
25 their friend. They speak to their broker. Maybe the broker

0

52

1 knows someone inside the company. They also have prices.
2 They have documents that are publicly filed.

3 It may be a whole confluence of issues. But as
4 long as the price of the stock is affected by what is
5 happening in the marketplace, and they haven't been able to
6 break that chain, then it matters not that the broker may
7 have spoken to some people inside the company.

8 Thank you.

9 MS. SHANAHAN: Your Honor, may I address my
10 summary judgment motion briefly?

11 THE COURT: Go ahead.

12 MS. SHANAHAN: We largely rest on the papers;
13 but as the Court is aware, the chronology goes that
14 Mr. Hoffman purchased his last set of Organogenesis stock on
15 April 13, 2000. Mr. Arcari did not join the company until
16 May 1st, 2000. And in the complaint the court sustained the
17 motion to dismiss does not describe any statements by
18 Mr. Arcari during the time frame in which Mr. Hoffman was
19 purchasing his stock.

20 And it's for that very reason that we submit that
21 under both the Constitution, Article III, and rulings of the
22 First Circuit and other courts, there is no standing for
23 Mr. Hoffman to sue Mr. Arcari because there is no connection
24 between any statements in the market at the time that
25 Mr. Hoffman purchased and anything done by Mr. Arcari.

2-5-07organogenesis.txt

53

1 Now, there is a suggestion in the plaintiffs'
2 response, which is a Rule 56(f) response, that this is an
3 issue that should be decided at a later date, perhaps on the
4 eve of trial after there is discovery. And I would submit
5 to the Court that that is incorrect really for three
6 reasons.

7 First, this motion does need to be decided now and
8 really in advance of certification motions. The law of the
9 circuit is clear that standing is a threshold issue. It has
10 to be decided before certification. And lead plaintiff
11 cannot bootstrap himself into class representative position
12 based on the class standing. He has to have standing in his
13 own right.

14 Secondly, as the Court pointed out, this case had a
15 motion to dismiss sustained based on certain described
16 statements allegedly made by the defendants.

17 Now, in their papers in opposition to summary
18 judgment plaintiffs seek to do additional discovery of
19 Mr. Arcari and of all the other defendants and numerous
20 third parties.

21 And I would submit that any discovery they do in
22 that case is essentially a fishing expedition in order to
23 find evidence that may or may not be a claim about what
24 Mr. Arcari had done very abstractly with the company before
25 he joined.

54

2-5-07organogenesis.txt

1 But the papers that we submitted in support of the
2 motion demonstrate that Mr. Arcari joined the company
3 May 1st, was not involved with the company before April 13th
4 and so that is not a warranted fishing expedition.

5 More importantly, as a matter of law, anything that
6 they seek to describe as potential evidence that they will
7 find doesn't rise above the level of what has been described
8 as aiding and abetting evidence.

9 And the Supreme Court decision in Central Bank has
10 held quite clearly that there is no liability for aiding and
11 abetting a 10(b) violation. There has to be an actual
12 statement made by the defendant that is the crux of his
13 liability.

14 Mr. Arcari didn't say or do anything at
15 Organogenesis prior to Mr. Hoffman's final purchase of
16 stock; and, therefore, the summary judgment motion is not an
17 academic exercise. It does need to be decided in advance of
18 the certification motion.

19 And it's particularly important in this case given
20 what Mr. Shapiro laid out in great detail with the problems
21 of Mr. Madigan's both standing and adequacy to prosecute
22 this case.

23 In the event that Mr. Hoffman remains as the sole
24 lead plaintiff, he cannot be a sole lead plaintiff in a
25 class with Mr. Arcari as the defendant.

55

1 THE COURT: Do you want to be heard?

2 MR. SLOANE: Thank you, Your Honor.

3 The defense counsel said that the defendant Arcari
Page 49

2-5-07organogenesis.txt

4 didn't say or do anything before he joined the company on
5 May 1st.

6 Now, it is important to understand that he formally
7 became employed with the company on May 1st and we
8 understand it as the chief financial officer but we don't
9 know what the defendant Arcari did before then.

10 The time period that we are talking about --

11 THE COURT: Does that help you that you don't
12 know? I mean, don't you have to know? You are bringing the
13 case.

14 MR. SLOANE: Well, Your Honor, we've alleged a
15 common course of conduct among the defendants to participate
16 in --

17 THE COURT: Do you have some good faith basis
18 for making that as an assertion?

19 MR. SLOANE: Yes, Your Honor. We have a
20 document that we have -- that we obtained that was, we
21 allege was created by the defendant Arcari, and that he has
22 not denied, that lists a number of actions by one of the
23 other defendants, defendant Albert Erani which would be
24 described charitably as suspicious activity. And that
25 activity goes back to March of 2000 which is the month

0

56

1 before Mr. Hoffman made his last purchase of stock and two
2 months before --

3 THE COURT: What does that have to do with
4 Arcari?

5 MR. SLOANE: It was the defendant Arcari who
6 created this document. He wrote it.

2-5-07organogenesis.txt

7 THE COURT: What do you say about that?

8 MS. SHANAHAN: Your Honor, the document that
9 they're referencing has a date of October 2001 on it. It's
10 a long list of chronology issues.

11 The two that Mr. Sloane is identifying that --
12 again, it's dated March 2000 -- relate to essentially
13 publicly available information. It doesn't indicate any
14 insider information or activity by Mr. Arcari in the March
15 2000 time frame. This is a document dated October 2001.

16 More importantly, the vast picture that the
17 plaintiffs can paint with these inference that there might
18 have been some, I don't know, meeting or whatnot that
19 Mr. Arcari attended at the company, which I don't believe
20 there is any basis for alleging, they have to allege that
21 Mr. Arcari made a statement, a public statement giving rise
22 to liability under securities laws.

23 There is no statement here. And given that there
24 is nothing in the complaint and there is nothing identified
25 that they say, oh, well, by the way, there is this other

57

1 statement that was out there made by Mr. Arcari, he simply
2 cannot be a defendant.

3 The courts have recently held in the Eighth Circuit
4 in the In Re: Turner Communications case and in other cases
5 that it's not enough for a third party to be sort of around
6 the periphery while the main defendants were making
7 statements. They have to have actually made statements
8 themselves in order to be liable under 10(b).

9 So even if this phantom evidence that I don't
Page 51

2-5-07organogenesis.txt

10 believe there is any basis for expecting it would be found,
11 even if such phantom evidence were found, it's just at best
12 aiding and abetting evidence.

13 And under the Central Bank decision out of the
14 Supreme Court, there is no liability for aiders and
15 abettors. That's not a pendent claim.

16 THE COURT: All right.

17 MR. SLOANE: May I briefly respond, Your
18 Honor?

19 THE COURT: Please.

20 MR. SLOANE: I'll first address the law and
21 then briefly address the facts.

22 With respect to the law, we're not trying to state
23 a claim for aiding and abetting liability.

24 There is primary -- excuse me -- primary liability
25 can be found, and I'm quoting now from the Swack case, I

□

58

1 mean, some cases found where a person substantially
2 participates in a manipulative or deceptive scheme even if a
3 material misstatement by another person creates the nexus
4 between the scheme and the securities market.

5 So we don't believe that it is necessary for the
6 defendant, for defendant Arcari to have made a public
7 statement in order to be held liable.

8 There are also other cases to that effect, Your
9 Honor, which we cite in our brief, including the Fezzani
10 case.

11 With respect to the facts that give rise to the
12 inference that he was involved in this scheme before he

2-5-07organogenesis.txt

13 joined the company, the document that I was referring to is
14 dated October of 2001. But we don't know when Mr. Arcari
15 possessed this knowledge or first came to possess this
16 knowledge about the company. We don't know what it says
17 about when he first came to be involved in this scheme or
18 this conspiracy.

19 Defense counsel says that this document says
20 nothing other than what was already publicly disclosed.

21 I'd like to read to Your Honor the two entries,
22 they're very brief, from March of 2000. And I submit that
23 these are not in any public filing.

24 This is an entry speaking about Albert Erani. It
25 says, "Drove board to approve 6.2 million dollar cash

59

1 redemption in Series C convertible preferred stock at a time
2 when the company had little cash. Could have redeemed for
3 stock but was dilution phobic."

4 The other entry says, "Did not sell stock off the
5 shelf when opportunity existed to sell more shares at \$14.50
6 per share."

7 The other issues in this document, Your Honor --

8 THE COURT: What is the significance of that,
9 in terms of anything other than to say it is historic
10 treatment of something that happened?

11 MR. SLOANE: Well, we don't know, Your Honor,
12 when -- this document doesn't say when, No. one,
13 defendant --

14 THE COURT: Well, it didn't say that
15 Mr. Arcari did anything. It is just a summary of some
Page 53

2-5-07organogenesis.txt

16 information. We don't know where he got it.

17 MR. SLOANE: That's right, Your Honor. But I
18 submit that we should have the opportunity to find out what
19 he does know about it, when he became involved, if he was
20 involved in any of this suspicious activity that's listed
21 here, including the manipulation or the attempted
22 manipulation of the market for the company's stock, and when
23 he became involved, if at all, in this scheme.

24 THE COURT: Well, to make it clear, then what
25 you are saying to me is that piece of paper which, for want

0

60

1 of a -- I don't know how we can identify it except to take
2 it and call it a court exhibit.

3 MR. SLOANE: Your Honor, if I may, this has
4 been submitted to the Court on a previous motion.

5 THE COURT: Well, I am sure it has. I want to
6 make sure that we are talking about the same piece of paper.
7 We will call it Court Exhibit 1 for the purposes of this
8 hearing. Okay. So we are literally on the same page.

9 Now, are you telling me that is all you have got?
10 If that isn't it, there is nothing else? With respect to
11 Acari.

12 MR. SLOANE: Well, what we're saying is that
13 on the basis --

14 THE COURT: That is a simple question. And I
15 don't want to press you but --

16 MR. SLOANE: At this point, yes, Your Honor.

17 THE COURT: That is a good, honest answer.

18 But this is the ball game for you at this point.

2-5-07organogenesis.txt

19 MR. SLOANE: Yes, Your Honor.

20 THE COURT: Okay.

21 MR. SLOANE: Before the conclusion of
22 discovery, yes.

23 THE COURT: Okay. Anything else?
24 Anything from anybody?

25 MR. SHAPIRO: Judge, I'm just reminded, if I

61

1 could just drop these (indicating) off with Ms. Lovett. We
2 have, for our chart we have our citations for everything
3 that's sort of on the box, that's in the boxes for the time
4 line. If I can just leave this off?

5 THE COURT: Okay. You can give those to her.
6 Thank you.

7 MR. SHAPIRO: Thank you, Judge.

8 THE COURT: Thank you very much.

9 Very well presented by everybody. You can't all
10 win unless you are smart and you go outside and settle the
11 case. That would be smart.

12 But short of that, then I just thank you very much
13 for helping me and I will do the best I can with it. All
14 right.

15 COUNSEL: Thank you, Your Honor.

16 MR. SLOANE: Your Honor, would you like me to
17 submit this (indicating)?

18 THE CLERK: Yes.

19 THE COURT: Yes. Just so we can have it. I
20 don't want everybody wondering what piece of paper we were
21 talking about.

2-5-07organogenesis.txt

22 (Court Exhibit No. 1 received in evidence.)
23 (Court Exhibit No. 2 received in evidence.)
24 (WHEREUPON, the proceedings were recessed at 12:20
25 p.m.)

0

62

C E R T I F I C A T E

I, Carol Lynn Scott, Official Court Reporter for the United States District Court for the District of Massachusetts, do hereby certify that the foregoing pages are a true and accurate transcription of my shorthand notes taken in the aforementioned matter to the best of my skill and ability.

CAROL LYNN SCOTT
Official Court Reporter
John J. Moakley Courthouse
1 Courthouse Way, Suite 7204
Boston, Massachusetts 02210
(617) 330-1377

2-5-07organogenesis.txt

0